JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 1,767 articles

Articles by James Calloway

Ondas Shares Surge on SEC Filing Amid Acquisition Spree Ahead of Q1 Earnings
Earnings

Ondas Shares Surge on SEC Filing Amid Acquisition Spree Ahead of Q1 Earnings

Ondas Inc. shares climbed over 4% Monday ahead of Q1 earnings, as SEC filings detailed share registrations for recent acquisitions including Mistral Inc. and World View Enterprises.

ONDS
Archer Aviation Faces Q1 Test Amid UAE Regulatory Progress
Earnings

Archer Aviation Faces Q1 Test Amid UAE Regulatory Progress

Archer Aviation reports Q1 earnings with a focus on certification milestones and cash burn. UAE regulatory advance boosts prospects for air taxi service.

ACHR JOBY
Nebius Shares Surge Ahead of Q1 Earnings as $18 Billion Capex Plan Faces Test
Earnings

Nebius Shares Surge Ahead of Q1 Earnings as $18 Billion Capex Plan Faces Test

Nebius Group shares surged to $190.98, approaching record highs, as investors await Q1 earnings. The AI cloud firm's $18 billion capex target and major deals with Meta and Microsoft are key.

NBIS
Oklo Earnings in Focus After NRC Design Approval
Earnings

Oklo Earnings in Focus After NRC Design Approval

Oklo Inc. reports Q1 earnings Tuesday, with analysts expecting a 19-cent loss, following NRC approval of key design criteria for its Aurora reactor.

OKLO META NVDA
WhiteFiber Q1 Results Due as NC-1 Data Center Revenue Ramp Begins
Earnings

WhiteFiber Q1 Results Due as NC-1 Data Center Revenue Ramp Begins

WhiteFiber reports Q1 earnings May 14 as its NC-1 data center begins billing under a $865M Nscale colocation deal. Revenue rose 61% in Q4 to $23.6M, but net loss was $1.5M.

CRWV IREN NVDA
AST SpaceMobile Earnings on Deck After FCC License and Launch Setback
Earnings

AST SpaceMobile Earnings on Deck After FCC License and Launch Setback

AST SpaceMobile reports Q1 earnings Monday after securing an FCC license for a 248-satellite direct-to-phone network, but a Blue Origin launch failure left its BlueBird 7 satellite in an unusable orbit.

ASTS
Circle Faces Q1 Earnings Test Amid Shifting Stablecoin Regulations
Earnings

Circle Faces Q1 Earnings Test Amid Shifting Stablecoin Regulations

Circle Internet Group reports Q1 earnings Monday before the market opens, with analysts expecting $0.19 EPS and $715M revenue, as USDC circulation surged 72%.

COIN
Eos Energy Stock Faces Critical Earnings Test After 26% Surge
Earnings

Eos Energy Stock Faces Critical Earnings Test After 26% Surge

Eos Energy Enterprises reports Q1 earnings on May 13 after a sharp rally. Revenue guidance of $56-57M and institutional buying from New Jersey pension fund and Vanguard set the stage.

EOSE
Everpure's Q1 Report: Analysts Optimistic Amid Rising Supply Costs
Earnings

Everpure's Q1 Report: Analysts Optimistic Amid Rising Supply Costs

Everpure Inc. is set to report its first fiscal Q1 2027 results on May 27, with analysts forecasting a 19% upside, though rising input costs for semiconductors pose a challenge.

Hims & Hers Earnings: Weight-Loss Strategy in Focus as GLP-1 Shift Unfolds
Earnings

Hims & Hers Earnings: Weight-Loss Strategy in Focus as GLP-1 Shift Unfolds

Hims & Hers Health reports Q1 earnings Monday after close, with Wall Street expecting ~$617M revenue. The key focus: how its weight-loss business performs after shifting from compounded GLP-1 drugs to FDA-approved options from Novo Nordisk.

HIMS LLY GDRX TNDM NVO
Pfizer's COVID Patent Woes Persist as Investors Eye Growth Beyond Vaccines
Regulation

Pfizer's COVID Patent Woes Persist as Investors Eye Growth Beyond Vaccines

A Delaware federal judge dismissed Acuitas Therapeutics' attempt to clear Pfizer's Comirnaty vaccine from GSK patent claims, leaving the patent dispute unresolved. Pfizer shares fell 1.42% to $25.68.

PFE GSK LLY
Trade Desk Stock Slumps as Q2 Revenue Forecast Misses Wall Street Targets
Earnings

Trade Desk Stock Slumps as Q2 Revenue Forecast Misses Wall Street Targets

The Trade Desk shares fell sharply after the company's Q2 revenue guidance of $750M missed analyst expectations of $771M, prompting multiple downgrades.

TTD